See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Bios Partners is a venture capital firm identifying advanced biotech in overlooked and under-invested markets in the U.S., which its team helps cultivate and bring to market. The firm's core thesis is that great science is evenly distributed throughout the country, yet venture capital tends to be concentrated on the coasts—especially in Silicon Valley and the Northeastern US. Bios seeks to disrupt this 'geographic favoritism' by investing in opportunities with equally compelling science across the Central US that are often overlooked and undervalued. The firm focuses on early-stage and growth-stage biopharmaceutical and medical device companies, leveraging a combined 90+ years of experience in hedge funds, private equity, clinical drug development, and public pharma/biotech analysis to fill the experiential void for portfolio company CEOs.
Notable quotes
“I would tell people, I'm the least connected guy on Wall Street. That was my catch phrase.”
“It is really rewarding and exciting to see an entrepreneur grow his/her idea into a company.”
“My focus now is on giving back.”
Team
Aaron G.L. Fletcher, PhD
Founder & Managing Director
Leslie W. Kreis, Jr.
Co-Founder & Partner
John Fucci
Partner
Amanda de la Garza
Partner
Blake Pate
Vice President of Investments
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Renibus Therapeutics | Series B | $111m | 2025-07-17 |
| Trefoil Therapeutics | Series B | — | 2025-05-06 |
| ONL Therapeutics | Series D | $65m | 2024-09-13 |
| Opus Genetics | Seed | $19m | 2021-09-23 |
| Actuate Therapeutics | Series B | $7m | 2019-11-12 |
| Azitra | Series A | $14m | 2019-10-15 |
| Lantern Pharma | Series A | — | — |
| Cognition Therapeutics | Series A | — | — |
| Taysha Gene Therapies | Series A | — | — |
| IN8bio | Series A | — | — |
Frequent co-investors
Fit check
Is Bios Partners a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit